TIRZEPATIDE 30 mg

Tirzepatide (10mg) – Dual GIP/GLP-1 Receptor Agonist

Advance metabolic research with Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Designed to target dual incretin pathways, Tirzepatide is extensively investigated for its significant role in glycemic control, lipid metabolism, appetite suppression, and body composition optimization.

Key Benefits:

• Dual Incretin Activation: Combines GIP and GLP-1 receptor pathways for enhanced metabolic synergy.
• Supports Weight & Appetite Control: Promotes prolonged satiety signaling and delays gastric emptying.
• Optimizes Glycemic Control: Enhances glucose-dependent insulin secretion while lowering glucagon levels.
• Promotes Metabolic Health: Evaluated for improving insulin sensitivity and lipid profiles.

Ideal For:

• Dual incretin pathway research
• Weight loss and appetite suppression studies
• Glycemic control and insulin sensitivity modeling
• Metabolic syndrome and cardiovascular health research

Typical research dosing ranges from 2.5 mg to 15 mg per week (administered once weekly).

Add 1mL of bacteriostatic water to get a solution that is 10mg/mL, such that every 0.1mL (10 units on an insulin syringe) is equal to 1mg of Tirzepatide.

Store unmixed vials in a cool, dark place away from direct light. Once reconstituted, this product must be refrigerated between 2°C – 8°C (36°F – 46°F) and used within 30 days.